<DOC>
	<DOC>NCT00762645</DOC>
	<brief_summary>The purpose of this study is to demonstrate that the Intraocular Pressure (IOP) lowering efficacy of Travoprost Ophthalmic Solution 0.004% is superior to that of Pilocarpine 1% in patients with chronic angle-closure glaucoma (CACG).</brief_summary>
	<brief_title>Travoprost 0.004% Versus Pilocarpine 1% in Patients With Chronic Angle Closure Glaucoma (CACG)</brief_title>
	<detailed_description />
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Glaucoma, Angle-Closure</mesh_term>
	<mesh_term>Travoprost</mesh_term>
	<mesh_term>Pilocarpine</mesh_term>
	<criteria>Age ≥ 18 years Chronic Angle Closure Glaucoma (CACG) 2135 millimeters mercury mean intraocular pressure on Eligibility visit day at 9 AM Peripheral iridotomy performed ≥ 1 Month prior to the Screening visit Anterior chamber angle in which the trabecular meshwork is not visible for ≥180 degrees in gonioscopy without indentation Peripheral anterior synechiae (PAS) Traumatic damage of the anterior chamber angle History of ocular inflammation or surgery (except for iridotomy) ≤ 3 months Patients who cannot be safely discontinued from use of all ocular hypotensive medication(s) for 12 days to 14 weeks Visual Acuity ≥ 1.0 Contact lenses wearer</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>IOP lowering efficacy</keyword>
	<keyword>CACG</keyword>
</DOC>